Journals in Pharmacology
Journals in Pharmacology
Elsevier's Pharmacology collection studies how drugs interact with biological systems to improve health and treat disease. It covers pharmacodynamics, exploring drug effects on biology, and pharmacokinetics, studying how the body affects drugs. Branches like Pharmacogenetics. Essential for pharmacologists, this collection offers invaluable insights into drug interactions, efficacy, and safety, crucial for advancing drug development and improving patient outcomes.
Clinical Microbiology Newsletter
Clinical Microbiology Newsletter is published four issues per year to provide consistent educational features and to keep pace with advances in the fast-moving field of Clinical Microbiology.Clinica... Microbiology Newsletter aims to provide articles to enable you to streamline procedures and improve results. It publishes reviews on infectious disease pathogens, reports on changes that affect your work, including articles on new diagnostic techniques, regulatory and guideline changes, and challenging diagnostic dogmas, clinical cases focused on diagnostic approaches for both common and uncommon pathogens.The journal publishes three types of articles:Mini-review... Case presentationsSnapsho... articles cover topics including:Minireview... on the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of infectious diseases,Practical articles on common and contemporary laboratory techniques,Indispens... updates on important clinical problems that impact the clinical laboratory,Editorial... and opinions on controversial issues in laboratory medicine,Case-based articles focused on diagnostic approaches for infectious pathogens,Snapshots highlighting specific infectious pathogens, therapeutic options, and diagnostic methodologies.Helpfu... tips on improving the laboratory workplace.- ISSN: 0196-4399
Pharmacology & Therapeutics
Pharmacology & Therapeutics presents lucid, critical and authoritative reviews of currently important topics in pharmacology, including the actions of drugs, and/or the exploitation of drug targets.Disease pathophysiology is relevant provided it is part of a narrative around drug actions or new drug targets.Pharmacology & Therapeutics only publishes invited review articles. Proposals for review articles are not accepted.Founded in 1976, Pharmacology & Therapeutics continues to be among the top 10 most cited journals in pharmacology.- ISSN: 0163-7258
Pulmonary Pharmacology & Therapeutics
Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.Research Areas Include:• All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary ToxicologyBefore submitting, please note the "Rules of 5" defining immediate rejection criteria of PPT:1. Out of scope: The paper should report on the use of pharmacological or toxicological studies (positive or negative) that are directly related to Pulmonary Pharmacology & Therapeutics.Immedia... rejection criteria are: a) Testing of extracts or plant parts that are not characterized b) Case Reports or n=1 studies2. Too preliminary: A paper must be based on a thorough and extensive study, using proper controlsImmediate rejection criteria are: a) In vitro studies with a single dose, or very high concentration b) Single dose studies with very few animals, no dose-response studies c) No proper controls. d) Repetition or confirmation of an earlier work3. Unethical: The study must have been carried under appropriate ethical approval for the study (either animal or human).4. Inappropriate experiments or lacking essential detailImmediate rejection criteria are: a) Wrong species or lacking details on the exact number of animals/subjects used b) No details of structure if a new drug is used for the first time5. Lack of novelty: The study must represent a novel approach to the field.Immediate rejection criteria are: a) Repetition of well known data b) No advance of knowledge in the fieldNote that only manuscripts written in good English will be considered by the Editors (British usage is preferred).- ISSN: 1094-5539
Vascular Pharmacology
Vascular Pharmacology is a journal of Vascular Biology and Medicine. We seek to rapidly publish transformative papers, reviews, and perspectives on vascular cells across the disciplines of biochemistry, pharmacology, pathology, physiology, molecular and developmental biology, and clinical medicine using sophisticated tools in genomics/proteomics/... genetics, genome editing, and bioengineering.The journal will consider submissions that address vascular cells in the context of:Atherosclerosis, thrombosis, hemostasisNeurovascu... diseasesDiabetes, obesity, and metabolic syndromePulmonary hypertensionCardiova... toxicity induced by anticancer drugsTransplant arteriopathyVascular aging, repair, and regenerationReperfus... injuryImmunological influence in vascular diseasesMicrovascula... dysfunctionPlease check the latest journal related topics and articles on our Twitter account @VasPharma.- ISSN: 1537-1891
Antiviral Research
Antiviral Research aims to publish manuscripts in the field of prevention and treatment of viral diseases in humans and vertebrate animals, and encourages authors to the submit manuscripts describing the activity of well-defined chemical compounds for the treatment of viral diseases. The journal is an Official Publication of the International Society for Antiviral Research. The types of papers published in Antiviral Research includes original research reports, short communications, commentaries and invited review* articles on the control of viral infections in humans. The journal’s scope encompasses:antivira... drugs, antibodies and host-response modifiers, including their synthesis, in vitro and in vivo testing and mechanisms of action.identificatio... and validation of new drug targets;laboratory animal models of viral diseases for antiviral efficacy testing;evolution of drug-resistant viruses and the development of effective counter measures;pathogenesi... of viral diseases and mechanisms of viral evasion of host immune responses;assessment... of drug safety;new or improved vaccines against viral infections of humans; the prevention and treatment of viral diseases of vertebrate animals, and reports of the testing of veterinary vaccines in the target animal species. All papers must include a sufficiently detailed description of methods to permit other investigators to replicate the experiments. Authors reporting the antiviral effect of a novel small-molecule drug must reveal its chemical structure. Claims of in vitro or in vivo efficacy of a drug or vaccine must be supported by appropriate statistical analysis that must be clearly described in the manuscript.Antiviral Research journal does not publish reports on viral diseases of plants or of insects, crustaceans or other invertebrates. Studies of viral diseases of livestock and companion animals must be clearly related to the development of realistic therapies. Papers on veterinary vaccines should report findings in the target animal species.We discourage the submission of manuscripts reporting the antiviral activity of unpurified natural products, or of partially purified substances of natural origin for which a mechanism of action has not been determined. Manuscripts claiming an antiviral effect of homeopathic products or other highly diluted preparations, or which fail to clearly identify the biological ingredient or molecule responsible for the antiviral activity of an experimental therapy, will not be considered for publication. Articles describing antiseptics with broad-spectrum antimicrobial activity will not be accepted. We discourage the submission of in silico docking studies or other computer-based predictions of antiviral activity that are not supported by data from biological assays. Citations of reports that have not undergone peer review must include the note "[not peer-reviewed]."ISAR members Authors who are ISAR members are encouraged to contact ISAR after their paper has been accepted for publication in order to benefit from their published work being highlighted in ISAR postings on their social media platforms (further details on this will be given in the AVR acceptance letter). *Antiviral Research journal has started a new initiative to publish at least two thematic special issues per year, containing invited reviews in addition to the ad hoc invitations to experts in the areas within the scope of the journal.- ISSN: 0166-3542
European Journal of Pharmaceutics and Biopharmaceutics
Official Journal of the International Association for Pharmaceutical TechnologyThe European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.Top... covered include for example:Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)Aspects of manufacturing process designBiomedical aspects of drug product designStrategies and formulations for controlled drug transport across biological barriersPhysicochemi... aspects of drug product developmentNovel excipients for drug product designDrug delivery and controlled release systems for systemic and local applicationsNanomate... for therapeutic and diagnostic purposesAdvanced therapy medicinal productsMedical devices supporting a distinct pharmacological effect"The Rules of 3"The Editors and Editorial board have developed the "Rules of 3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work: 1. The paper must report on novel findings that are not merely an unprecedented combination of known aspects in pharmaceutics and biopharmaceutics of major importance. 2. A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented. 3. The study described in the manuscript must not merely confirm the state of the art in the field of pharmaceutics and biopharmaceutics, but advance it.- ISSN: 0939-6411
Toxicology Letters
Official Journal of EUROTOXAffiliated with Austrian Society of ToxicologyAn international journal for the rapid publication of novel reports on a range of aspects of toxicology, especially mechanisms of toxicity.Toxicology Letters serves as a multidisciplinary forum for research in toxicology. The prime aim is the rapid publication of research studies that are both novel and advance our understanding of a particular area. In addition to hypothesis-driven studies on mechanisms of mammalian toxicity, Toxicology Letters welcomes seminal work in the following areas:In silico toxicologyToxicokine... pharmacokinetic (PBPK) modelingSystems toxicologyPredictive toxicology3R research in toxicologyNew approach methodology (NAMs)Adverse outcome pathways (AOPs)Integrated testing strategiesSystematic and narrative reviews and mini-reviews in various areas of toxicology will be published. Clinical, occupational and safety evaluation, hazard and risk assessment, regulatory toxicology, impact on man, animal and environment studies of sufficient novelty to warrant rapid publication will be considered. Toxicology Letters also publishes editorials, commentaries and contemporary issues in toxicology.The following types of work are not within the scopes of Toxicology Letters:Ecotoxicolog... studiesCase studiesChemopreventi... studiesPharmacologic... investigationsAuthor... are advised to follow the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments; https://arriveguidel... and the OECD guidance document on Good In Vitro Method Practices (GIVIMP; https://www.oecd.org... In vitro or in vivo investigations conducted at concentrations or doses of no relevance to human or animal exposure will not be considered. Routes of exposure other than those relevant to human or animal exposure need to be justified. Assessment of dose-response should be an integral component of any toxicological research report. Unless adequately justified, studies conducted at a single dose level may not be considered. Test materials must be chemically defined and characterized. Investigations of chemically undefined plant extracts or uncharacterized nanoparticles will not be considered.- ISSN: 0378-4274
Journal of Controlled Release
The Journal of Controlled Release (JCR) is the Official Journal of the Controlled Release Society, and of the Japan Society of Drug Delivery System.It publishes high-quality research articles in the broad field of delivery science and technology. This includes drug delivery systems and all aspects of formulations, such as physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development in the disciplines of pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.Manuscrip... that advance fundamental understanding of principles and/or demonstrate advantages of novel technologies in safety and efficacy over current clinical standards will be given priority.- ISSN: 0168-3659
Fitoterapia
The Journal for the Study of Medicinal PlantsA Q1-ranked journal in the category of 'Agricultural and Biological Sciences' (Scopus).Fitoterapia is a Journal dedicated to medicinal plants and fungi and to the bioactive natural products produced by these organisms. It publishes original contributions in seven major areas:1. Chemical characterization of active ingredients of medicinal plants and fungi, including their endophytes 2. New analytical approaches for dereplication and standardization of biologically active extracts and metabolites from plant resources 3. Identification of bioactivity in plant and fungal extracts and in their constituents 4. Identification of biological targets and mechanism of activity of plant and fungal extracts 5. Production and genomic characterization of medicinal plants biomass 6. Biosynthesis of bioactive natural products of plant, fungi and endophytic origin 7. Critical reviews of the composition, history, clinical and legal status of medicinal plants, and accounts on topical issues.Contributions reporting the following are NOT normally considered for publication: 1. Activity data on crude extracts that have not been characterized by analysis of their major constituents (HPLC fingerprint, LC/MS or NMR). Data on the extract composition simply taken from the literature are not acceptable. Characterization of only a few constituents is generally considered too partial. 2. Studies on the bioactivity of pure compounds purchased or obtained by Authors without any study or relationship with the producing organism. 3. Unexceptional and predictable bioactivity (e.g. antioxidant properties of phenolics or antibacterial activity of essential oils). 4. Uncritical ethnopharmacological investigations, where a list of plants and their use are simply recorded. 5. Genomic, transcriptomic and pharmacological studies without convincing wet lab experiments, or with little correlation to bioactive natural compounds.In addition, the following immediate rejection criteria apply: RULE 1: The manuscript does not fall into any of the areas of interest of the Journal. RULE 2: The manuscript is too preliminary, reporting e.g. activity data without comparison to a reference, or without a positive control. RULE 3: The botanical source is not clearly identified, authenticated, and documented (voucher). RULE 4: Characterization of new compounds without spectral supporting material. RULE 5: Bioactivity is not relevant to in vivo situations. RULE 6: Reviews on topics already covered in the recent literature.- ISSN: 0367-326X
Environmental Toxicology and Pharmacology
Environmental Toxicology and Pharmacology publishes the results of studies concerning toxic and pharmacological effects of (human and veterinary) drugs and of environmental contaminants in animals and man.Areas of special interest are: molecular mechanisms of toxicity, biotransformation and toxicokinetics (including toxicokinetic modelling), molecular, biochemical and physiological mechanisms explaining differences in sensitivity between species and individuals, the characterisation of pathophysiological models and mechanisms involved in the development of effects and the identification of biological markers that can be used to study exposure and effects in man and animals.In addition to full length papers, short communications, full-length reviews and mini-reviews, Environmental Toxicology and Pharmacology will publish in depth assessments of special problem areas. The latter publications may exceed the length of a full length paper three to fourfold. A basic requirement is that the assessments are made under the auspices of international groups of leading experts in the fields concerned. The information examined may either consist of data that were already published, or of new data that were obtained within the framework of collaborative research programmes. Provision is also made for the acceptance of minireviews on (classes of) compounds, toxicities or mechanisms, debating recent advances in rapidly developing fields that fall within the scope of the journal.- ISSN: 1382-6689
